All In Biotech

Drug Trial Radar · NCT04586907

A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3537021 in Healthy Participants and Patients With Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Dec 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

85

Actual

Start

Nov 23, 2020

Primary completion

Nov 30, 2021

Study completion Nov 30, 2021

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Oct 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 21 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to learn more about the safety of LY3537021 and any side effects that might be associated with it in healthy participants and participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to check how much LY3537021 gets into the bloodstream and how long the body takes to eliminate it. This study will last up to about 19 weeks including screening period.

Conditions

  • Healthy
  • Type 2 Diabetes Mellitus

Interventions

  • LY3537021Drug

    Administered SC.

  • PlaceboDrug

    Administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline through Day 119 (Part A) and Day 57 (Part B)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lilly Centre for Clinical Pharmacology

    Singapore, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.